Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Rheumatology

Why It’s Not Scleroderma: Differentiating EF from Other Conditions

At a Glance

Eosinophilic Fasciitis (EF) is distinct from scleroderma because it does not cause Raynaud's phenomenon, spares the face and fingers, and does not damage internal organs. A deep biopsy is required to accurately diagnose EF because it affects the deep fascia tissue rather than upper skin layers.

It is very common for patients with Eosinophilic Fasciitis (EF) to be told at first that they might have Scleroderma (systemic sclerosis) or Morphea. These conditions belong to a family of “sclerosing” disorders, which all cause the skin to become hard or thick [1][2]. However, EF is a distinct disease with a different biological “blueprint.” Getting the diagnosis exactly right is crucial because the treatment and long-term outlook for EF differ significantly from other conditions [3][4].

Clinical Clues: What’s Missing?

One of the most powerful ways doctors distinguish EF from systemic sclerosis is by evaluating your physical signs and looking for what is not there.

  • No Raynaud’s Phenomenon: In systemic sclerosis, nearly all patients suffer from Raynaud’s phenomenon—a condition where the fingers turn white or blue and become painful when exposed to cold [5][6]. In EF, Raynaud’s is almost never present [7][8].
  • Sparing the Face and Fingers: Systemic sclerosis typically begins in the fingers (sclerodactyly) and can affect the face [9]. EF is unique because it almost always spares the face, hands, and feet, focusing instead on the forearms, legs, and trunk [9][7].
  • No Internal Organ Damage: While systemic sclerosis can affect the lungs, heart, and kidneys, EF is generally limited to the fascia and skin, though it can cause significant joint stiffness [7][2].

Biological and Pathological Differences

Beneath the microscope, EF and its “look-alikes” reveal very different origins.

  • Different Depth: Morphea primarily affects the upper layers of the skin, whereas EF is rooted much deeper, in the fascia [10][11]. This is why a deep, full-thickness biopsy is the only way to tell them apart [12].
  • Distinct Cellular Markers: Pathologists look for specific cellular markers under the microscope to definitively distinguish between the two diseases. Because EF and morphea originate from different cellular building blocks, the pattern of these markers helps doctors confirm an EF diagnosis without relying on confusing medical jargon [1].
  • Eosinophil Infiltration: As the name suggests, EF biopsies often show an influx of eosinophils (a type of white blood cell) into the fascia, a feature not typically seen in standard scleroderma [13][10].

Why the Correct Label Matters

While both EF and scleroderma may be treated with steroids initially, their long-term management is different [14][15]. EF often responds very well to high-dose corticosteroids, and adding a second-line drug like methotrexate early on can help prevent permanent joint stiffness [12][14]. Because EF can be “triggered” by specific events like intense exercise or certain cancer medications, identifying it correctly allows your doctor to address the root cause and provide a clearer map for your recovery [11][16].

Common questions in this guide

Why is eosinophilic fasciitis often mistaken for scleroderma?
Both conditions are 'sclerosing' disorders, meaning they cause the skin to become hard or thick. Because the initial physical symptoms look similar, patients with EF are frequently misdiagnosed with scleroderma or morphea before deep tissue biopsies are performed.
Does eosinophilic fasciitis cause Raynaud's phenomenon?
No. Unlike systemic sclerosis (scleroderma), eosinophilic fasciitis almost never causes Raynaud’s phenomenon. If your fingers do not turn white or blue and become painful when exposed to cold, it is a strong clinical clue pointing toward EF rather than scleroderma.
What areas of the body does eosinophilic fasciitis affect?
EF typically focuses on the forearms, legs, and trunk of the body. One of the main ways it differs from scleroderma is that it almost always spares the face, hands, and feet.
How do doctors definitively tell the difference between EF and morphea?
Because morphea affects the upper layers of the skin and EF is rooted much deeper in the fascia, a deep, full-thickness biopsy is the only way to tell them apart. A pathologist will look for specific cellular markers, like an influx of white blood cells called eosinophils, to confirm EF.
Why does the exact diagnosis between EF and scleroderma matter for my treatment?
While both conditions might initially use steroids, their long-term management is different. EF often responds excellently to high-dose corticosteroids and early use of methotrexate, which can prevent permanent joint stiffness. Getting the exact diagnosis ensures you are on the right long-term recovery path.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does the absence of Raynaud’s phenomenon in my case point more toward EF than systemic sclerosis?
  2. 2.Why is it important to distinguish EF from systemic sclerosis before deciding on my long-term treatment plan?
  3. 3.Are my 'groove sign' and 'peau d'orange' findings consistent with EF rather than other skin-thickening conditions?
  4. 4.If my fingers and face are unaffected, does that effectively rule out systemic sclerosis as a diagnosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    A case of eosinophilic fasciitis and generalized morphea overlap.

    Watanabe Y, Yamamoto M, Yamamoto T

    Dermatology online journal 2020; (26(2)).

    PMID: 32239898
  2. 2

    An unusual case of eosinophilia, myalgia and skin contractures: Shulman's disease revisited.

    Anadure RK, Shankar S, Mohimen A, et al.

    Medical journal, Armed Forces India 2022; (78(Suppl 1)):S273-S276 doi:10.1016/j.mjafi.2019.12.006.

    PMID: 36147388
  3. 3

    Eosinophilic fasciitis difficult to differentiate from scleroderma: A case report.

    Lan TY, Wang ZH, Kong WP, et al.

    World journal of clinical cases 2023; (11(13)):3092-3098 doi:10.12998/wjcc.v11.i13.3092.

    PMID: 37215414
  4. 4

    Juvenile eosinophilic fasciitis: three case reports with review of the literature.

    Papa R, Nozza P, Granata C, et al.

    Clinical and experimental rheumatology 2016; (34(3)):527-30.

    PMID: 27268780
  5. 5

    Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.

    Fernández-Codina A, Cañas-Ruano E, Pope JE

    Journal of scleroderma and related disorders 2019; (4(2)):102-110 doi:10.1177/2397198318823951.

    PMID: 35382396
  6. 6

    Raynaud's Phenomenon with Focus on Systemic Sclerosis.

    Maciejewska M, Sikora M, Maciejewski C, et al.

    Journal of clinical medicine 2022; (11(9)) doi:10.3390/jcm11092490.

    PMID: 35566614
  7. 7

    Morphea and Eosinophilic Fasciitis: An Update.

    Mertens JS, Seyger MMB, Thurlings RM, et al.

    American journal of clinical dermatology 2017; (18(4)):491-512 doi:10.1007/s40257-017-0269-x.

    PMID: 28303481
  8. 8

    Controversy around the morphea.

    Dańczak-Pazdrowska A, Cieplewicz P, Żaba R, et al.

    Postepy dermatologii i alergologii 2021; (38(5)):716-720 doi:10.5114/ada.2021.106242.

    PMID: 34849114
  9. 9

    Eosinophilic Fasciitis and Smoldering Multiple Myeloma: An Exceptional Association in Young Adults.

    Jabbouri R, Bouanani N, Aniq Filali R, Aasfara J

    Cureus 2022; (14(4)):e23896 doi:10.7759/cureus.23896.

    PMID: 35530826
  10. 10

    A difficult diagnosis of eosinophilic fasciitis: A case report.

    Mihailescu M, Abbas M

    SAGE open medical case reports 2024; (12()):2050313X241231384 doi:10.1177/2050313X241231384.

    PMID: 38665934
  11. 11

    Groove Sign in Eosinophilic Fasciitis.

    Mourad AI, Lehman JS, Mydlarski PR

    Mayo Clinic proceedings 2021; (96(8)):2184 doi:10.1016/j.mayocp.2021.04.001.

    PMID: 34353471
  12. 12

    Diagnosis and treatment of early eosinophilic fasciitis: a case report.

    Ma J, Cai Y, Shao H, et al.

    Journal of medical case reports 2025; (19(1)):373 doi:10.1186/s13256-025-05440-7.

    PMID: 40731023
  13. 13

    Eosinophilic Fasciitis Without Skin Sclerosis.

    Komori K, Rokutanda R

    The Journal of rheumatology 2023; (50(7)):963-964 doi:10.3899/jrheum.220600.

    PMID: 36455945
  14. 14

    Eosinophilic fasciitis.

    Lamback EB, Resende FS, Lenzi TC

    Anais brasileiros de dermatologia 2016; (91(5 suppl 1)):57-59 doi:10.1590/abd1806-4841.20164683.

    PMID: 28300895
  15. 15

    Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission.

    Tull R, Hoover WD, De Luca JF, et al.

    Drugs in context 2018; (7()):212529 doi:10.7573/dic.212529.

    PMID: 30302114
  16. 16

    Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.

    Boppana SH, Dulla NR, Beutler BD, et al.

    The American journal of case reports 2021; (22()):e932888 doi:10.12659/AJCR.932888.

    PMID: 34403405

This page explains the differences between eosinophilic fasciitis and systemic sclerosis for educational purposes. Always consult your rheumatologist or dermatologist for an accurate diagnosis and treatment plan.

Get notified when new evidence is published on Eosinophilic fasciitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.